Meier and coauthors found that topotecan improved progression-free and overall survival compared with treosulfan in patients with recurrent ovarian cancer following platinum and taxane-based therapy.

6 Another trial has demonstrated superior overall survival for patients treated with topotecan and cisplatin compared with paclitaxel and cisplatin. 5 The GOG-204 trial demonstrated similar ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Four CPT analogs, namely trastuzumab derukstekan, topotecan, belotecan, and irinotecan, have been approved as part of chemotherapy treatments. However, the investigation continues into their ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Present anti-cancer drugs — camptothecin, topotecan, and irinotecan — target a molecule (the enzyme topoisomerase 1 or Top1) involved in DNA metabolic processes like replication and transcription.

Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage ...

Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase III for Triple-Negative Breast Cancer (TNBC).

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...